Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jul 1;5(7):1060-1062.
doi: 10.1001/jamaoncol.2019.0869.

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Bram De Laere  1   2 , Prabhakar Rajan  3 , Henrik Grönberg  1 , Luc Dirix  2   4 , Johan Lindberg  5 ; CORE-ARV-CTC and ProBIO Investigators
Affiliations
Clinical Trial

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Bram De Laere et al. JAMA Oncol. .

Erratum in

  • Error in the Figure.
    [No authors listed] [No authors listed] JAMA Oncol. 2019 Jul 1;5(7):1070. doi: 10.1001/jamaoncol.2019.2255. JAMA Oncol. 2019. PMID: 31294757 Free PMC article. No abstract available.

Abstract

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs De Laere and Dirix have patent WO2017207702 pending: Androgen receptor splice variants and androgen deprivation therapy. No other disclosures were reported.

Figures

Figure.
Figure.. Androgen Receptor Burden in Baseline Liquid Biopsy Specimens From Patients With TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer and Progression-Free Survival on Androgen Receptor Signaling Inhibitors
A, Kaplan-Meier analysis of progression-free survival in 80 patients, stratified according to the number of androgen receptor (AR) perturbations at baseline. The P value was calculated via log-rank test. The black dashed lines represent the median progression-free survival time. B, Multivariable Cox regression analysis (hazard ratio and 95% CI) of progression-free survival using baseline characteristics and the number of AR perturbations. The P value was calculated using the Wald test of Z statistic. ARSi indicates AR signaling inhibitor; CT, chemotherapy; ctDNA, circulating tumor DNA; PFS, progression-free survival; PSA, prostate-specific antigen. aOne observation was deleted due to missing baseline PSA measurement. bVariables were log transformed.
See this image and copyright information in PMC

References

    1. Antonarakis ES, Lu C, Luber B, et al. . Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149-2156. doi:10.1200/JCO.2016.70.1961 - DOI - PMC - PubMed
    1. Conteduca V, Wetterskog D, Sharabiani MTA, et al. ; PREMIERE Collaborators; Spanish Oncology Genitourinary Group . Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28(7):1508-1516. doi:10.1093/annonc/mdx155 - DOI - PMC - PubMed
    1. Plymate SR, Sharp A, de Bono JS. Nuclear circulating tumor cell androgen receptor variant 7 in castration-resistant prostate cancer: the devil is in the detail. JAMA Oncol. 2018;4(9):1187-1188. doi:10.1001/jamaoncol.2018.1615 - DOI - PubMed
    1. Annala M, Vandekerkhove G, Khalaf D, et al. . Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444-457. doi:10.1158/2159-8290.CD-17-0937 - DOI - PubMed
    1. De Laere B, van Dam P-J, Whitington T, et al. . Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns. Eur Urol. 2017;72(2):192-200. doi:10.1016/j.eururo.2017.01.011 - DOI - PubMed

MeSH terms